Aalborg University Hospital
Verified
Aalborg, Denmark
Not yet recruiting
Feasibility Study of Clostridium Botulinum Neurotoxin Type A for Chronic Postsurgical Pain in Lung Cancer Patients
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
What is this trial about?
A plain-language summary of the goals, design and what participants do
A group of people who have undergone surgery for lung cancer sometimes continue to feel pain for months after the operation. This ongoing discomfort is called Chronic postsurgical pain. The study will use a medication known as Botulinum toxin A, supplied as the product Xeomin, which is given by a small injection under the skin of the chest wall.
The purpose of the study is to find out whether it is possible to run a larger trial that tests whether this medication can safely reduce the long‑lasting pain that some patients experience after lung cancer surgery.
Participants who meet the basic criteria will be asked to join, receive the injection, and then complete a series of brief questionnaires about their pain and any side effects at several follow‑up visits. The study will track how many people agree to join, how many complete the treatment and follow‑up, and will collect information on how well the injection method is tolerated.
The research process
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
Who can join the trial?
7 criteria
- Be 18 years old or older.
- Have had lung cancer surgery that was intended to cure the cancer, whether or not you also received extra treatment before or after the operation.
- Have chronic postsurgical pain that continues for a long time after the lung cancer surgery, as defined by the International Association for the Study of Pain.
- Feel at least moderate pain, which means you rate your pain 4 or higher on a 0‑to‑10 numerical rating scale (NRS), or you have nerve‑related pain that scores 4 or higher on the DN4 questionnaire (a short survey used to identify nerve pain).
- Be able to understand, speak, and read Danish.
- If you are a woman who could become pregnant, you must use a safe and approved form of birth control (contraceptive treatment).
- Both men and women are allowed to participate.
Who cannot join the trial?
10 criteria
- Cannot understand the spoken or written information about the study.
- Pregnant, breastfeeding, planning to become pregnant, or a woman who can become pregnant and is not using reliable birth control such as hormonal methods or an intrauterine device.
- Had lung cancer surgery that was not completely removed according to the final pathology report (not a radical treatment).
- Is having examinations or treatments for another cancer at the same time.
- Had chronic pain in the chest area before the lung surgery.
- Has autoimmune neuromuscular diseases (where the immune system attacks nerves or muscles), multiple sclerosis, peripheral neuromuscular disorders, or severe overall muscle weakness or wasting.
- Is allergic or overly sensitive (hypersensitive) to BTX‑A.
- Is currently receiving BTX‑A treatment or received it within the past year.
- Has psychiatric problems that the investigators think would make it hard to take part in the study.
- Is actively abusing illegal drugs.
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Verified sites
All sites with verified contact details – recruitment status may not be available; ask directly
Trial locations
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingNot finding your country?
Not sure what to do next?
Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Investigated drugs
Xeomin is a medication that contains a purified form of botulinum toxin type A. In this study it is injected under the skin near the area where patients had lung cancer surgery. The purpose of the injection is to see if the toxin can block the nerve signals that cause chronic pain after surgery. Researchers are testing whether this treatment can safely reduce pain and whether a larger trial could be done in the future.
What is already known about the treatment
Xeomin - It comes as a sterile solution for subcutaneous injection, each vial providing 100 international units of botulinum toxin type A that is free of complexing proteins. The product is an approved drug widely used for conditions such as muscle spasticity, cosmetic wrinkle reduction, and some pain disorders, and it is well documented in medical literature. It works by blocking the release of acetylcholine at nerve endings, which reduces muscle activity and also dampens pain‑signal transmission. Pharmacologically, it is classified as a botulinum neurotoxin (ATC code M03AX01).
Investigated diseases
Chronic postsurgical pain (CPSP) - Chronic postsurgical pain is pain that lasts for at least three months after a surgical procedure, beyond the usual healing period. It typically appears in the area of the incision or nearby tissues and may feel like aching, burning, or pressure. The pain can begin soon after surgery and may become steady or fluctuate over time. It may spread to surrounding regions as the nervous system becomes more sensitive. If not addressed, the discomfort can gradually increase during everyday activities.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2026-525669-33-00Protocol codeBTX-CPSPEstimated enrolment15 patientsSponsorAalborg University Hospital
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?